Garvan Institute Integrates Geneformics Technology to Reduce Genomics Data Footprint

Garvan Institute of Medical Research to Integrate Geneformics Technology Into its Genomic Data Storage and Archive Workflows for Research

SUNNYVALE, Calif.--()--Geneformics Data Systems Limited, a leader in Genomics IT Infrastructures that advance the accessibility of transfer, storage and archiving of Next Generation Sequencing (NGS) today announced that the Garvan Institute of Medical Research will integrate Geneformics technology into its workflows. The Garvan Institute was one of the first centers in the world to acquire advanced next generation sequencing technology that is capable of sequencing up to 18,000 genomes a year.

Storage and archive of genomic data is becoming a huge challenge for the industry with a single whole human genome (WGS) generating approximately 300GB of raw, uncompressed data. Other compression technologies can reduce file size between 25 and 33 percent, while Geneformics true lossless technology compression reduces whole genome data size by up to 95 percent. Integrating Geneformics workflows means genomic data occupies a smaller footprint, which reduces storage costs, enables easier data sharing and increases flexibility to compute in other environments like the cloud.

“The combination of Geneformics’ technology and Garvan’s workflow will enable Garvan to benefit from storage and archiving of key bioIT and medical discoveries,” said Rafael Feitelberg, Geneformics CEO. “With our true lossless compression, we mitigate hurdles, making the data accessible so organizations can focus on genomic data insights including precision medicine research.”

“We looked for a solution to reduce our genomic data footprint and after extensive evaluation and testing, Geneformics was the clear choice,” said Warren Kaplan, Chief of Informatics at the Garvan Institute. “Geneformics offers superior compression ratio, the full integrity and lossless aspect of their solution and higher compression and decompression speed. By providing one of the most powerful technology platforms for using sequence data at scale and in real-time, we have the capabilities and know-how required to generate and deploy the necessary data to identify key variants in the genome that underlie an individual’s phenotype.”

For more information on Geneformics or to schedule a demo, visit www.geneformics.com.

Geneformics is a technology leader in genomic data management and compression. Based on proprietary technology co-developed by the company’s bioinformaticians, computer engineers and the Weizmann Institute, Geneformics makes genomic data accessible by mitigating the complexity of massive data sets. The company’s solutions are implemented globally to optimize data transfer, storage and archiving, enabling the positive impact of precision. With offices in Silicon Valley and Israel, Geneformics is backed by international venture capital.

About the Garvan Institute

The Garvan Institute of Medical Research is one of Australia's largest medical research institutions and is at the forefront of next-generation genomic sequencing in Australia. Garvan’s main research areas are: cancer, diabetes and metabolism, immunology and inflammation, osteoporosis and bone biology, genomics and epigenetics, and neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health.

Contacts

for Geneformics
Marla Kertzman, +1 209-852-9027
marla@thoroughbred-communications.com

Release Summary

Geneformics announced that the Garvan Institute of Medical Research will integrate Geneformics technology into its workflows

Contacts

for Geneformics
Marla Kertzman, +1 209-852-9027
marla@thoroughbred-communications.com